Sweden as a pharmaceutical manufacturing country
Based on a blog post by NorthX Biologics CEO Janet Hoogstraate at Stockholm Science City Foundation JANET HOOGSTRAATE: Sweden holds a unique position in Life Sciences and has, for decades, been ...
NorthX Biologics is providing expert plasmid DNA solutions for all phases ranging from early pre-clinical through to commercial manufacture. We offer a range of plasmid qualities with the right level of control for every purpose, ensuring efficient expedition of your program with full regulatory compliance. We are providing pDNA as critical starting material for viral vector gene therapies and mRNA applications but also complete drug product manufacturing including aseptic fill/finish for pDNA vaccines and other modalities.
By applying our flexible proprietary platform process we can deliver high quality plasmids with compressed timelines facilitating speed to market. We are using aligned processes ensuring scalability from small to large scale with full in-house analytical support. In our modern innovation labs, we are providing full development services to meet you specific needs for optimization and process adaptions. By applying a structured R&D model we help to mitigate later manufacturing risks.
Read more by clicking the link below.
NorthX Biologics is a CDMO and Innovation Hub in Advanced Biologics, with +30 years of GMP production experience. The team provides process development and GMP manufacturing services with expertise in plasmid DNA, mRNA, proteins, cells and other advanced biologics. Headquartered in the heart of Sweden, the team serves customers worldwide and in 2021 was recognized as a national innovation hub for advanced therapeutics and vaccines. NorthX Biologics has the ambition to become a leading cell and gene therapy manufacturer and partner of choice for innovative drug development companies.
For more news, follow us on LinkedIn
Based on a blog post by NorthX Biologics CEO Janet Hoogstraate at Stockholm Science City Foundation JANET HOOGSTRAATE: Sweden holds a unique position in Life Sciences and has, for decades, been ...
The pharmaceutical industry is experiencing a rapid transformation as advanced biologics—viral vectors, recombinant proteins, plasmid DNA, and cell and gene therapies—take center stage. With over 14,800 active biologics innovation programs ...
The study of proteins is transforming our understanding of human biology and disease, enabling breakthroughs in diagnostics, drug development, and advanced therapies. In this article, Mathias Uhlén, Professor of Microbiology ...